Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ972MR)

This product GTTS-WQ972MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ972MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ414MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ6804MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ11826MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ3876MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ14426MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ3842MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ4075MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ4153MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754091
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW